Anti-Mouse CD103 (ITGAE) – Dylight® 650

Anti-Mouse CD103 (ITGAE) – Dylight® 650

Product No.: C909

- -
- -
Formats AvailableView All
Product Type
Monoclonal Antibody
Alternate Names
Integrin, alpha E, ITGAE
IF Microscopy

- -
- -
Select Product Size
- -
- -

Antibody Details

Product Details

Reactive Species
Host Species
Armenian Hamster
This CD103 antibody was produced using recombinant mouse CD103
Product Concentration
0.2 mg/ml
This DyLight® 650 conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Storage and Handling
This DyLight® 650 conjugate is stable when stored at 2-8°C. Do not freeze.
Country of Origin
Excitation Laser
Red Laser (652 nm)
Applications and Recommended Usage?
Quality Tested by Leinco
Additional Applications Reported In Literature ?
IF Microscopy
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.


Anti-CD103 antibody (clone 2E7) activity is directed against mouse CD103 (αE integrin).
Antigen Distribution
CD103 is expressed on intraepithelial lymphocytes, mucosa- and epithelial associated T lymphocytes, various populations of dendritic cells, dendritic epidermal T cells, some TGF β1 cells, and subsets of peripheral T cells, innate lymphoid cells, mast cells, and thymocytes.
CD103 integrin is a heterodimeric transmembrane receptor formed by the dimerization of αE (CD103) with β71,2. CD103 plays a role in intestinal homeostasis and inflammation3, is a key molecule in T cell activation1, and also functions within the tumor microenvironment1. CD103 integrin plays a role in the anti-tumor activities of tissue resident memory T cells (TRM), a type of memory T cell that is part of the adaptive immune system and also protects human epithelial tissues against inflammatory and infectious disease1. TRM are defined by expression of CD103 and CD49a integrins and the C-type lectin CD691. Additionally, CD103 is recruited at the immune synapse formed between cytotoxic T lymphocytes and epithelial tumor cells1, is required for polarized exocytosis of lytic granules leading to target cell lysis1, and migratory CD103+ dendritic cells are important for the initiation of cytotoxic T cell responses4.

CD103 integrin binds to E-cadherin1,2. TGFβ increases the affinity of CD103 for E-cadherin through phosphorylation of integrin-linked kinase, induces CD103 on TCR-engaged antigen-specific CD8+ T cells, and is also directly involved in CD103 activation.

The 2E7 clone was originally used to define CD103 integrin expression in lymphocyte subsets and during T cell ontogeny5. 2E7 was shown to be reactive against CD103 integrin by immunoprecipitation.

Antigen Details

NCBI Gene Bank ID
Research Area
Cell Adhesion

References & Citations

1. Mami-Chouaib F, Blanc C, Corgnac S, et al. J Immunother Cancer. 6(1):87. 2018.
2. Hoffmann JC, Schön MP. Cancers (Basel). 13(24):6211. 2021.
3. Jaensson E, Uronen-Hansson H, Pabst O, et al. J Exp Med. 205(9):2139-2149. 2008.
4. Hong Y, Kim YK, Kim GB, et al. J Extracell Vesicles. 8(1):1670893. 2019.
5. Lefrançois L, Barrett TA, Havran WL, et al. Eur J Immunol. 24(3):635-640. 1994.
6. Mysorekar IU, Lorenz RG, Gordon JI. J Biol Chem. 277(40):37811-37819. 2002.
7. Xiao B, Wang Y, Reinach PS, et al. PLoS One. 10(1):e0115333. 2015.
8. Sierro F, Evrard M, Rizzetto S, et al. Immunity. 47(2):374-388.e6. 2017.
9. Bedoui S, Whitney PG, Waithman J, et al. Nat Immunol. 10(5):488-495. 2009.
10. Edelson BT, KC W, Juang R, et al. J Exp Med. 207(4):823-836. 2010.
11. del Rio ML, Cote-Sierra J, Rodriguez-Barbosa JI. Transpl Int. 24(5):501-513. 2011.
12. Mikami N, Matsushita H, Kato T, et al. J Immunol. 186(12):6886-6893. 2011.
13. Mackay LK, Rahimpour A, Ma JZ, et al. Nat Immunol. 14(12):1294-1301. 2013.
14. Quinn KM, Yamamoto A, Costa A, et al. J Immunol. 191(10):5085-5096. 2013.
15. Blankenhaus B, Reitz M, Brenz Y, et al. PLoS Pathog. 10(2):e1003913. 2014.
16. Iwata A, Kawashima S, Kobayashi M, et al. Int Immunol. 26(2):103-114. 2014.
17. Guo X, Tanaka Y, Kondo M. Immunol Lett. 163(1):40-48. 2015.
18. Lee LM, Ji M, Sinha M, et al. PLoS One. 11(12):e0167693. 2016.
19. Herndler-Brandstetter D, Ishigame H, Shinnakasu R, et al. Immunity. 48(4):716-729.e8. 2018.
20. Tordesillas L, Lozano-Ojalvo D, Dunkin D, et al. Nat Commun. 9(1):5238. 2018.
21. Ge C, Monk IR, Pizzolla A, et al. Cell Rep. 29(13):4236-4244.e3. 2019.
22. Nelson CE, Thompson EA, Quarnstrom CF, et al. Cell Rep. 17;28(12):3092-3104.e5. 2019.
23. Niven J, Madelon N, Page N, et al. Cell Rep. 28(1):21-29.e6. 2019.
24. Sasaki K, Himeno A, Nakagawa T, et al. Nat Commun. 10(1):3878. 2019.
25. Yue X, Lio CJ, Samaniego-Castruita D, et al. Nat Commun. 10(1):2011. 2019.
26. Hassan AO, Kafai NM, Dmitriev IP, et al. Cell. 183(1):169-184.e13. 2020.
Flow Cytometry
IF Microscopy
Immunoprecipitation Protocol
Products are for research use only. Not for use in diagnostic or therapeutic procedures.